nodes	percent_of_prediction	percent_of_DWPC	metapath
Imipramine—CYP2B6—Thiotepa—sarcoma	0.118	0.163	CbGbCtD
Imipramine—SLC22A3—Vincristine—sarcoma	0.114	0.157	CbGbCtD
Imipramine—CYP2E1—Dacarbazine—sarcoma	0.0664	0.0915	CbGbCtD
Imipramine—CYP2E1—Mitoxantrone—sarcoma	0.0515	0.071	CbGbCtD
Imipramine—CYP1A2—Dacarbazine—sarcoma	0.0384	0.0529	CbGbCtD
Imipramine—CYP3A7—Vincristine—sarcoma	0.0367	0.0506	CbGbCtD
Imipramine—CYP3A7-CYP3A51P—Vincristine—sarcoma	0.0367	0.0506	CbGbCtD
Imipramine—CYP3A4—Thiotepa—sarcoma	0.0363	0.0501	CbGbCtD
Imipramine—CYP2E1—Etoposide—sarcoma	0.0325	0.0448	CbGbCtD
Imipramine—ABCB1—Dactinomycin—sarcoma	0.0291	0.0401	CbGbCtD
Imipramine—ABCB1—Mitoxantrone—sarcoma	0.026	0.0359	CbGbCtD
Imipramine—CYP2B6—Doxorubicin—sarcoma	0.0219	0.0301	CbGbCtD
Imipramine—CYP1A2—Etoposide—sarcoma	0.0188	0.0259	CbGbCtD
Imipramine—ABCB1—Vincristine—sarcoma	0.0179	0.0247	CbGbCtD
Imipramine—ABCB1—Etoposide—sarcoma	0.0164	0.0226	CbGbCtD
Imipramine—CYP3A4—Mitoxantrone—sarcoma	0.0156	0.0215	CbGbCtD
Imipramine—ABCB1—Doxorubicin—sarcoma	0.0112	0.0154	CbGbCtD
Imipramine—CYP3A4—Vincristine—sarcoma	0.0107	0.0148	CbGbCtD
Imipramine—CYP2D6—Doxorubicin—sarcoma	0.0106	0.0146	CbGbCtD
Imipramine—CYP3A4—Etoposide—sarcoma	0.00984	0.0136	CbGbCtD
Imipramine—CYP3A4—Doxorubicin—sarcoma	0.00671	0.00926	CbGbCtD
Imipramine—CHRM3—muscle of abdomen—sarcoma	0.00518	0.0706	CbGeAlD
Imipramine—SLC22A4—larynx—sarcoma	0.00433	0.059	CbGeAlD
Imipramine—HTR7—pulmonary artery—sarcoma	0.00417	0.0569	CbGeAlD
Imipramine—HTR2A—pulmonary artery—sarcoma	0.0026	0.0355	CbGeAlD
Imipramine—KCND2—myometrium—sarcoma	0.00216	0.0295	CbGeAlD
Imipramine—HTR2A—hindlimb—sarcoma	0.00157	0.0215	CbGeAlD
Imipramine—SLC22A4—mammary gland—sarcoma	0.0014	0.0191	CbGeAlD
Imipramine—HTR2A—appendage—sarcoma	0.00135	0.0184	CbGeAlD
Imipramine—HTR7—endothelium—sarcoma	0.00131	0.0178	CbGeAlD
Imipramine—KCND3—cardiac atrium—sarcoma	0.00123	0.0168	CbGeAlD
Imipramine—KCND3—uterus—sarcoma	0.00122	0.0167	CbGeAlD
Imipramine—CHRM5—skin of body—sarcoma	0.00105	0.0143	CbGeAlD
Imipramine—KCND2—testis—sarcoma	0.00102	0.0139	CbGeAlD
Imipramine—SLC22A4—myometrium—sarcoma	0.000994	0.0136	CbGeAlD
Imipramine—SLC22A3—myometrium—sarcoma	0.000905	0.0123	CbGeAlD
Imipramine—SLC22A4—seminal vesicle—sarcoma	0.000898	0.0122	CbGeAlD
Imipramine—ORM1—hematopoietic system—sarcoma	0.000887	0.0121	CbGeAlD
Imipramine—KCND3—testis—sarcoma	0.000887	0.0121	CbGeAlD
Imipramine—SLC22A3—embryo—sarcoma	0.00087	0.0119	CbGeAlD
Imipramine—CHRM4—testis—sarcoma	0.000845	0.0115	CbGeAlD
Imipramine—KCND3—liver—sarcoma	0.000839	0.0114	CbGeAlD
Imipramine—SLC6A3—hematopoietic system—sarcoma	0.000825	0.0113	CbGeAlD
Imipramine—SLC22A3—seminal vesicle—sarcoma	0.000817	0.0111	CbGeAlD
Imipramine—HTR2A—endothelium—sarcoma	0.000815	0.0111	CbGeAlD
Imipramine—SLC22A3—hematopoietic system—sarcoma	0.000777	0.0106	CbGeAlD
Imipramine—CYP2C18—liver—sarcoma	0.000764	0.0104	CbGeAlD
Imipramine—SLC6A4—hematopoietic system—sarcoma	0.000756	0.0103	CbGeAlD
Imipramine—SLC22A3—connective tissue—sarcoma	0.000748	0.0102	CbGeAlD
Imipramine—CYP3A7—liver—sarcoma	0.000727	0.00991	CbGeAlD
Imipramine—KCNH2—myometrium—sarcoma	0.000696	0.00949	CbGeAlD
Imipramine—SLC22A3—smooth muscle tissue—sarcoma	0.000684	0.00933	CbGeAlD
Imipramine—HTR1A—hematopoietic system—sarcoma	0.000671	0.00915	CbGeAlD
Imipramine—KCND3—lymph node—sarcoma	0.000643	0.00877	CbGeAlD
Imipramine—HTR7—hematopoietic system—sarcoma	0.000642	0.00875	CbGeAlD
Imipramine—KCNH2—seminal vesicle—sarcoma	0.000629	0.00857	CbGeAlD
Imipramine—CYP2C19—hematopoietic system—sarcoma	0.000627	0.00854	CbGeAlD
Imipramine—ADRA1A—hematopoietic system—sarcoma	0.000619	0.00844	CbGeAlD
Imipramine—CYP3A7-CYP3A51P—liver—sarcoma	0.000618	0.00842	CbGeAlD
Imipramine—HTR7—connective tissue—sarcoma	0.000618	0.00842	CbGeAlD
Imipramine—KCNH2—hematopoietic system—sarcoma	0.000598	0.00815	CbGeAlD
Imipramine—CHRM3—smooth muscle tissue—sarcoma	0.000594	0.0081	CbGeAlD
Imipramine—ORM1—bone marrow—sarcoma	0.000569	0.00776	CbGeAlD
Imipramine—HTR7—smooth muscle tissue—sarcoma	0.000565	0.00771	CbGeAlD
Imipramine—SLC22A4—tendon—sarcoma	0.000565	0.0077	CbGeAlD
Imipramine—HRH1—myometrium—sarcoma	0.000558	0.00761	CbGeAlD
Imipramine—SLC22A4—bone marrow—sarcoma	0.000547	0.00746	CbGeAlD
Imipramine—CYP1A2—hematopoietic system—sarcoma	0.000512	0.00698	CbGeAlD
Imipramine—CYP2B6—hematopoietic system—sarcoma	0.000491	0.00669	CbGeAlD
Imipramine—CYP2E1—seminal vesicle—sarcoma	0.000484	0.0066	CbGeAlD
Imipramine—HRH1—hematopoietic system—sarcoma	0.000479	0.00653	CbGeAlD
Imipramine—HRH1—connective tissue—sarcoma	0.000461	0.00629	CbGeAlD
Imipramine—CYP2E1—hematopoietic system—sarcoma	0.00046	0.00628	CbGeAlD
Imipramine—ORM1—liver—sarcoma	0.00046	0.00627	CbGeAlD
Imipramine—KCNH2—cardiac atrium—sarcoma	0.000454	0.00619	CbGeAlD
Imipramine—SLC6A3—testis—sarcoma	0.000452	0.00617	CbGeAlD
Imipramine—KCNH2—uterus—sarcoma	0.000451	0.00616	CbGeAlD
Imipramine—HTR2A—embryo—sarcoma	0.000448	0.00611	CbGeAlD
Imipramine—ADRA1A—lymphoid tissue—sarcoma	0.000436	0.00594	CbGeAlD
Imipramine—CYP2B6—skin of body—sarcoma	0.000426	0.00581	CbGeAlD
Imipramine—SLC22A3—testis—sarcoma	0.000426	0.0058	CbGeAlD
Imipramine—HTR7—tendon—sarcoma	0.000425	0.00579	CbGeAlD
Imipramine—HRH1—smooth muscle tissue—sarcoma	0.000422	0.00575	CbGeAlD
Imipramine—SLC22A1—liver—sarcoma	0.000421	0.00574	CbGeAlD
Imipramine—SLC22A3—liver—sarcoma	0.000402	0.00549	CbGeAlD
Imipramine—HTR2A—hematopoietic system—sarcoma	0.0004	0.00546	CbGeAlD
Imipramine—HTR2A—connective tissue—sarcoma	0.000385	0.00525	CbGeAlD
Imipramine—KCNH2—bone marrow—sarcoma	0.000383	0.00522	CbGeAlD
Imipramine—CYP3A4—hematopoietic system—sarcoma	0.00037	0.00505	CbGeAlD
Imipramine—CHRM3—testis—sarcoma	0.000369	0.00504	CbGeAlD
Imipramine—Mood swings—Epirubicin—sarcoma	0.000367	0.00184	CcSEcCtD
Imipramine—Paraesthesia—Mitoxantrone—sarcoma	0.000366	0.00184	CcSEcCtD
Imipramine—Loss of consciousness—Etoposide—sarcoma	0.000365	0.00183	CcSEcCtD
Imipramine—Cerebrovascular accident—Doxorubicin—sarcoma	0.000365	0.00183	CcSEcCtD
Imipramine—SLC6A2—testis—sarcoma	0.000365	0.00497	CbGeAlD
Imipramine—CYP2D6—hematopoietic system—sarcoma	0.000364	0.00497	CbGeAlD
Imipramine—Decreased appetite—Vincristine—sarcoma	0.000364	0.00183	CcSEcCtD
Imipramine—Ataxia—Epirubicin—sarcoma	0.000364	0.00183	CcSEcCtD
Imipramine—Somnolence—Mitoxantrone—sarcoma	0.000363	0.00182	CcSEcCtD
Imipramine—Gastrointestinal disorder—Vincristine—sarcoma	0.000362	0.00181	CcSEcCtD
Imipramine—Fatigue—Vincristine—sarcoma	0.000361	0.00181	CcSEcCtD
Imipramine—Convulsion—Etoposide—sarcoma	0.00036	0.00181	CcSEcCtD
Imipramine—Dyspepsia—Mitoxantrone—sarcoma	0.000359	0.0018	CcSEcCtD
Imipramine—Hypertension—Etoposide—sarcoma	0.000359	0.0018	CcSEcCtD
Imipramine—Constipation—Vincristine—sarcoma	0.000358	0.0018	CcSEcCtD
Imipramine—Liver function test abnormal—Epirubicin—sarcoma	0.000357	0.00179	CcSEcCtD
Imipramine—Decreased appetite—Mitoxantrone—sarcoma	0.000355	0.00178	CcSEcCtD
Imipramine—Orthostatic hypotension—Epirubicin—sarcoma	0.000353	0.00177	CcSEcCtD
Imipramine—ORM1—lymph node—sarcoma	0.000352	0.00481	CbGeAlD
Imipramine—Affect lability—Doxorubicin—sarcoma	0.000352	0.00177	CcSEcCtD
Imipramine—HTR2A—smooth muscle tissue—sarcoma	0.000352	0.00481	CbGeAlD
Imipramine—Fatigue—Mitoxantrone—sarcoma	0.000352	0.00176	CcSEcCtD
Imipramine—HTR7—testis—sarcoma	0.000352	0.00479	CbGeAlD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—sarcoma	0.000352	0.00176	CcSEcCtD
Imipramine—Discomfort—Etoposide—sarcoma	0.00035	0.00175	CcSEcCtD
Imipramine—Breast disorder—Epirubicin—sarcoma	0.00035	0.00175	CcSEcCtD
Imipramine—Constipation—Mitoxantrone—sarcoma	0.000349	0.00175	CcSEcCtD
Imipramine—CYP2B6—lymphoid tissue—sarcoma	0.000345	0.00471	CbGeAlD
Imipramine—Gastrointestinal pain—Vincristine—sarcoma	0.000343	0.00172	CcSEcCtD
Imipramine—Confusional state—Etoposide—sarcoma	0.000342	0.00172	CcSEcCtD
Imipramine—Anaphylactic shock—Etoposide—sarcoma	0.000339	0.0017	CcSEcCtD
Imipramine—Mood swings—Doxorubicin—sarcoma	0.000339	0.0017	CcSEcCtD
Imipramine—SLC22A4—lymph node—sarcoma	0.000339	0.00462	CbGeAlD
Imipramine—Asthenia—Thiotepa—sarcoma	0.000339	0.0017	CcSEcCtD
Imipramine—Infection—Etoposide—sarcoma	0.000337	0.00169	CcSEcCtD
Imipramine—Ataxia—Doxorubicin—sarcoma	0.000337	0.00169	CcSEcCtD
Imipramine—Asthenia—Dactinomycin—sarcoma	0.000336	0.00169	CcSEcCtD
Imipramine—Feeling abnormal—Mitoxantrone—sarcoma	0.000336	0.00169	CcSEcCtD
Imipramine—Pruritus—Thiotepa—sarcoma	0.000334	0.00168	CcSEcCtD
Imipramine—Gastrointestinal pain—Mitoxantrone—sarcoma	0.000334	0.00167	CcSEcCtD
Imipramine—DRD2—testis—sarcoma	0.000332	0.00453	CbGeAlD
Imipramine—HTR7—liver—sarcoma	0.000332	0.00453	CbGeAlD
Imipramine—Thrombocytopenia—Etoposide—sarcoma	0.000332	0.00167	CcSEcCtD
Imipramine—Tachycardia—Etoposide—sarcoma	0.000331	0.00166	CcSEcCtD
Imipramine—Eosinophilia—Epirubicin—sarcoma	0.000331	0.00166	CcSEcCtD
Imipramine—Abdominal pain—Vincristine—sarcoma	0.000331	0.00166	CcSEcCtD
Imipramine—Body temperature increased—Vincristine—sarcoma	0.000331	0.00166	CcSEcCtD
Imipramine—Liver function test abnormal—Doxorubicin—sarcoma	0.000331	0.00166	CcSEcCtD
Imipramine—Skin disorder—Etoposide—sarcoma	0.00033	0.00165	CcSEcCtD
Imipramine—Hyperhidrosis—Etoposide—sarcoma	0.000328	0.00165	CcSEcCtD
Imipramine—KCNH2—testis—sarcoma	0.000328	0.00447	CbGeAlD
Imipramine—Orthostatic hypotension—Doxorubicin—sarcoma	0.000327	0.00164	CcSEcCtD
Imipramine—CYP2C19—liver—sarcoma	0.000325	0.00443	CbGeAlD
Imipramine—CYP2E1—lymphoid tissue—sarcoma	0.000324	0.00442	CbGeAlD
Imipramine—Urticaria—Mitoxantrone—sarcoma	0.000324	0.00163	CcSEcCtD
Imipramine—Breast disorder—Doxorubicin—sarcoma	0.000324	0.00162	CcSEcCtD
Imipramine—Anorexia—Etoposide—sarcoma	0.000323	0.00162	CcSEcCtD
Imipramine—Diarrhoea—Thiotepa—sarcoma	0.000323	0.00162	CcSEcCtD
Imipramine—Body temperature increased—Mitoxantrone—sarcoma	0.000322	0.00162	CcSEcCtD
Imipramine—Abdominal pain—Mitoxantrone—sarcoma	0.000322	0.00162	CcSEcCtD
Imipramine—Diarrhoea—Dactinomycin—sarcoma	0.000321	0.00161	CcSEcCtD
Imipramine—ADRA1A—liver—sarcoma	0.000321	0.00437	CbGeAlD
Imipramine—Pancytopenia—Epirubicin—sarcoma	0.000318	0.00159	CcSEcCtD
Imipramine—HRH1—tendon—sarcoma	0.000317	0.00432	CbGeAlD
Imipramine—Dizziness—Thiotepa—sarcoma	0.000312	0.00157	CcSEcCtD
Imipramine—Pollakiuria—Epirubicin—sarcoma	0.000309	0.00155	CcSEcCtD
Imipramine—SLC22A3—lymph node—sarcoma	0.000309	0.00421	CbGeAlD
Imipramine—Eosinophilia—Doxorubicin—sarcoma	0.000306	0.00154	CcSEcCtD
Imipramine—ABCB1—myometrium—sarcoma	0.000305	0.00416	CbGeAlD
Imipramine—Photosensitivity reaction—Epirubicin—sarcoma	0.000305	0.00153	CcSEcCtD
Imipramine—Paraesthesia—Etoposide—sarcoma	0.000305	0.00153	CcSEcCtD
Imipramine—CYP2E1—tendon—sarcoma	0.000305	0.00415	CbGeAlD
Imipramine—Weight increased—Epirubicin—sarcoma	0.000304	0.00153	CcSEcCtD
Imipramine—Weight decreased—Epirubicin—sarcoma	0.000303	0.00152	CcSEcCtD
Imipramine—Somnolence—Etoposide—sarcoma	0.000302	0.00151	CcSEcCtD
Imipramine—Asthenia—Vincristine—sarcoma	0.000301	0.00151	CcSEcCtD
Imipramine—Vomiting—Thiotepa—sarcoma	0.0003	0.00151	CcSEcCtD
Imipramine—Infestation—Epirubicin—sarcoma	0.000298	0.0015	CcSEcCtD
Imipramine—Drowsiness—Epirubicin—sarcoma	0.000298	0.0015	CcSEcCtD
Imipramine—Infestation NOS—Epirubicin—sarcoma	0.000298	0.0015	CcSEcCtD
Imipramine—Vomiting—Dactinomycin—sarcoma	0.000298	0.0015	CcSEcCtD
Imipramine—Rash—Thiotepa—sarcoma	0.000298	0.00149	CcSEcCtD
Imipramine—Dermatitis—Thiotepa—sarcoma	0.000298	0.00149	CcSEcCtD
Imipramine—Headache—Thiotepa—sarcoma	0.000296	0.00148	CcSEcCtD
Imipramine—Rash—Dactinomycin—sarcoma	0.000296	0.00148	CcSEcCtD
Imipramine—Decreased appetite—Etoposide—sarcoma	0.000295	0.00148	CcSEcCtD
Imipramine—Pancytopenia—Doxorubicin—sarcoma	0.000294	0.00147	CcSEcCtD
Imipramine—ABCB1—embryo—sarcoma	0.000294	0.004	CbGeAlD
Imipramine—Gastrointestinal disorder—Etoposide—sarcoma	0.000293	0.00147	CcSEcCtD
Imipramine—Asthenia—Mitoxantrone—sarcoma	0.000293	0.00147	CcSEcCtD
Imipramine—Fatigue—Etoposide—sarcoma	0.000293	0.00147	CcSEcCtD
Imipramine—Neuropathy peripheral—Epirubicin—sarcoma	0.000292	0.00147	CcSEcCtD
Imipramine—Jaundice—Epirubicin—sarcoma	0.000291	0.00146	CcSEcCtD
Imipramine—Stomatitis—Epirubicin—sarcoma	0.000291	0.00146	CcSEcCtD
Imipramine—Constipation—Etoposide—sarcoma	0.00029	0.00146	CcSEcCtD
Imipramine—Diarrhoea—Vincristine—sarcoma	0.000287	0.00144	CcSEcCtD
Imipramine—Pollakiuria—Doxorubicin—sarcoma	0.000286	0.00143	CcSEcCtD
Imipramine—Photosensitivity reaction—Doxorubicin—sarcoma	0.000282	0.00142	CcSEcCtD
Imipramine—Hepatobiliary disease—Epirubicin—sarcoma	0.000282	0.00141	CcSEcCtD
Imipramine—Weight increased—Doxorubicin—sarcoma	0.000282	0.00141	CcSEcCtD
Imipramine—Nausea—Thiotepa—sarcoma	0.000281	0.00141	CcSEcCtD
Imipramine—Weight decreased—Doxorubicin—sarcoma	0.00028	0.0014	CcSEcCtD
Imipramine—Feeling abnormal—Etoposide—sarcoma	0.00028	0.0014	CcSEcCtD
Imipramine—Diarrhoea—Mitoxantrone—sarcoma	0.000279	0.0014	CcSEcCtD
Imipramine—Nausea—Dactinomycin—sarcoma	0.000278	0.0014	CcSEcCtD
Imipramine—Agranulocytosis—Epirubicin—sarcoma	0.000278	0.0014	CcSEcCtD
Imipramine—Gastrointestinal pain—Etoposide—sarcoma	0.000277	0.00139	CcSEcCtD
Imipramine—Dizziness—Vincristine—sarcoma	0.000277	0.00139	CcSEcCtD
Imipramine—Drowsiness—Doxorubicin—sarcoma	0.000276	0.00138	CcSEcCtD
Imipramine—Infestation—Doxorubicin—sarcoma	0.000276	0.00138	CcSEcCtD
Imipramine—Infestation NOS—Doxorubicin—sarcoma	0.000276	0.00138	CcSEcCtD
Imipramine—ABCB1—seminal vesicle—sarcoma	0.000276	0.00376	CbGeAlD
Imipramine—Neuropathy peripheral—Doxorubicin—sarcoma	0.00027	0.00136	CcSEcCtD
Imipramine—Urticaria—Etoposide—sarcoma	0.00027	0.00135	CcSEcCtD
Imipramine—Jaundice—Doxorubicin—sarcoma	0.000269	0.00135	CcSEcCtD
Imipramine—Stomatitis—Doxorubicin—sarcoma	0.000269	0.00135	CcSEcCtD
Imipramine—CYP2B6—testis—sarcoma	0.000269	0.00367	CbGeAlD
Imipramine—Body temperature increased—Etoposide—sarcoma	0.000268	0.00135	CcSEcCtD
Imipramine—Abdominal pain—Etoposide—sarcoma	0.000268	0.00135	CcSEcCtD
Imipramine—Hepatitis—Epirubicin—sarcoma	0.000268	0.00134	CcSEcCtD
Imipramine—Hypoaesthesia—Epirubicin—sarcoma	0.000266	0.00134	CcSEcCtD
Imipramine—Vomiting—Vincristine—sarcoma	0.000266	0.00134	CcSEcCtD
Imipramine—CYP1A2—liver—sarcoma	0.000265	0.00361	CbGeAlD
Imipramine—HTR2A—tendon—sarcoma	0.000265	0.00361	CbGeAlD
Imipramine—SLC6A2—lymph node—sarcoma	0.000264	0.00361	CbGeAlD
Imipramine—Urinary tract disorder—Epirubicin—sarcoma	0.000264	0.00133	CcSEcCtD
Imipramine—Rash—Vincristine—sarcoma	0.000264	0.00132	CcSEcCtD
Imipramine—Dermatitis—Vincristine—sarcoma	0.000264	0.00132	CcSEcCtD
Imipramine—HRH1—testis—sarcoma	0.000263	0.00358	CbGeAlD
Imipramine—Urethral disorder—Epirubicin—sarcoma	0.000262	0.00132	CcSEcCtD
Imipramine—Headache—Vincristine—sarcoma	0.000262	0.00132	CcSEcCtD
Imipramine—ABCB1—hematopoietic system—sarcoma	0.000262	0.00357	CbGeAlD
Imipramine—Hepatobiliary disease—Doxorubicin—sarcoma	0.000261	0.00131	CcSEcCtD
Imipramine—Vomiting—Mitoxantrone—sarcoma	0.000259	0.0013	CcSEcCtD
Imipramine—Agranulocytosis—Doxorubicin—sarcoma	0.000258	0.00129	CcSEcCtD
Imipramine—Rash—Mitoxantrone—sarcoma	0.000257	0.00129	CcSEcCtD
Imipramine—Dermatitis—Mitoxantrone—sarcoma	0.000257	0.00129	CcSEcCtD
Imipramine—Headache—Mitoxantrone—sarcoma	0.000256	0.00128	CcSEcCtD
Imipramine—CYP2B6—liver—sarcoma	0.000254	0.00347	CbGeAlD
Imipramine—CYP2E1—testis—sarcoma	0.000252	0.00344	CbGeAlD
Imipramine—Eye disorder—Epirubicin—sarcoma	0.00025	0.00125	CcSEcCtD
Imipramine—Tinnitus—Epirubicin—sarcoma	0.00025	0.00125	CcSEcCtD
Imipramine—Nausea—Vincristine—sarcoma	0.000249	0.00125	CcSEcCtD
Imipramine—Cardiac disorder—Epirubicin—sarcoma	0.000248	0.00125	CcSEcCtD
Imipramine—Flushing—Epirubicin—sarcoma	0.000248	0.00125	CcSEcCtD
Imipramine—Hepatitis—Doxorubicin—sarcoma	0.000248	0.00124	CcSEcCtD
Imipramine—Hypoaesthesia—Doxorubicin—sarcoma	0.000246	0.00124	CcSEcCtD
Imipramine—Urinary tract disorder—Doxorubicin—sarcoma	0.000245	0.00123	CcSEcCtD
Imipramine—Asthenia—Etoposide—sarcoma	0.000243	0.00122	CcSEcCtD
Imipramine—Angiopathy—Epirubicin—sarcoma	0.000243	0.00122	CcSEcCtD
Imipramine—Urethral disorder—Doxorubicin—sarcoma	0.000243	0.00122	CcSEcCtD
Imipramine—Nausea—Mitoxantrone—sarcoma	0.000242	0.00122	CcSEcCtD
Imipramine—Immune system disorder—Epirubicin—sarcoma	0.000242	0.00121	CcSEcCtD
Imipramine—Mediastinal disorder—Epirubicin—sarcoma	0.000241	0.00121	CcSEcCtD
Imipramine—Pruritus—Etoposide—sarcoma	0.00024	0.0012	CcSEcCtD
Imipramine—Arrhythmia—Epirubicin—sarcoma	0.000239	0.0012	CcSEcCtD
Imipramine—CYP2E1—liver—sarcoma	0.000238	0.00325	CbGeAlD
Imipramine—KCNH2—lymph node—sarcoma	0.000237	0.00324	CbGeAlD
Imipramine—Alopecia—Epirubicin—sarcoma	0.000237	0.00119	CcSEcCtD
Imipramine—Mental disorder—Epirubicin—sarcoma	0.000235	0.00118	CcSEcCtD
Imipramine—Malnutrition—Epirubicin—sarcoma	0.000233	0.00117	CcSEcCtD
Imipramine—Diarrhoea—Etoposide—sarcoma	0.000232	0.00116	CcSEcCtD
Imipramine—Eye disorder—Doxorubicin—sarcoma	0.000231	0.00116	CcSEcCtD
Imipramine—Tinnitus—Doxorubicin—sarcoma	0.000231	0.00116	CcSEcCtD
Imipramine—Flushing—Doxorubicin—sarcoma	0.00023	0.00115	CcSEcCtD
Imipramine—Cardiac disorder—Doxorubicin—sarcoma	0.00023	0.00115	CcSEcCtD
Imipramine—Tension—Epirubicin—sarcoma	0.000229	0.00115	CcSEcCtD
Imipramine—Dysgeusia—Epirubicin—sarcoma	0.000228	0.00114	CcSEcCtD
Imipramine—Nervousness—Epirubicin—sarcoma	0.000226	0.00114	CcSEcCtD
Imipramine—Angiopathy—Doxorubicin—sarcoma	0.000225	0.00113	CcSEcCtD
Imipramine—Dizziness—Etoposide—sarcoma	0.000224	0.00113	CcSEcCtD
Imipramine—Immune system disorder—Doxorubicin—sarcoma	0.000224	0.00112	CcSEcCtD
Imipramine—Mediastinal disorder—Doxorubicin—sarcoma	0.000223	0.00112	CcSEcCtD
Imipramine—Arrhythmia—Doxorubicin—sarcoma	0.000221	0.00111	CcSEcCtD
Imipramine—Vision blurred—Epirubicin—sarcoma	0.00022	0.0011	CcSEcCtD
Imipramine—HTR2A—testis—sarcoma	0.000219	0.00299	CbGeAlD
Imipramine—Alopecia—Doxorubicin—sarcoma	0.000219	0.0011	CcSEcCtD
Imipramine—Mental disorder—Doxorubicin—sarcoma	0.000217	0.00109	CcSEcCtD
Imipramine—Ill-defined disorder—Epirubicin—sarcoma	0.000216	0.00108	CcSEcCtD
Imipramine—Vomiting—Etoposide—sarcoma	0.000216	0.00108	CcSEcCtD
Imipramine—Malnutrition—Doxorubicin—sarcoma	0.000216	0.00108	CcSEcCtD
Imipramine—Agitation—Epirubicin—sarcoma	0.000214	0.00107	CcSEcCtD
Imipramine—Rash—Etoposide—sarcoma	0.000214	0.00107	CcSEcCtD
Imipramine—Dermatitis—Etoposide—sarcoma	0.000214	0.00107	CcSEcCtD
Imipramine—Headache—Etoposide—sarcoma	0.000213	0.00107	CcSEcCtD
Imipramine—Tension—Doxorubicin—sarcoma	0.000212	0.00106	CcSEcCtD
Imipramine—Dysgeusia—Doxorubicin—sarcoma	0.000211	0.00106	CcSEcCtD
Imipramine—Malaise—Epirubicin—sarcoma	0.00021	0.00105	CcSEcCtD
Imipramine—Nervousness—Doxorubicin—sarcoma	0.000209	0.00105	CcSEcCtD
Imipramine—Syncope—Epirubicin—sarcoma	0.000209	0.00105	CcSEcCtD
Imipramine—Leukopenia—Epirubicin—sarcoma	0.000209	0.00105	CcSEcCtD
Imipramine—HTR2A—liver—sarcoma	0.000207	0.00283	CbGeAlD
Imipramine—Palpitations—Epirubicin—sarcoma	0.000206	0.00103	CcSEcCtD
Imipramine—Loss of consciousness—Epirubicin—sarcoma	0.000205	0.00103	CcSEcCtD
Imipramine—Vision blurred—Doxorubicin—sarcoma	0.000203	0.00102	CcSEcCtD
Imipramine—Convulsion—Epirubicin—sarcoma	0.000202	0.00101	CcSEcCtD
Imipramine—Nausea—Etoposide—sarcoma	0.000202	0.00101	CcSEcCtD
Imipramine—Hypertension—Epirubicin—sarcoma	0.000201	0.00101	CcSEcCtD
Imipramine—Ill-defined disorder—Doxorubicin—sarcoma	0.0002	0.001	CcSEcCtD
Imipramine—CYP2D6—testis—sarcoma	0.0002	0.00272	CbGeAlD
Imipramine—Agitation—Doxorubicin—sarcoma	0.000198	0.000994	CcSEcCtD
Imipramine—ABCB1—uterus—sarcoma	0.000198	0.0027	CbGeAlD
Imipramine—Anxiety—Epirubicin—sarcoma	0.000198	0.000992	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—sarcoma	0.000197	0.000988	CcSEcCtD
Imipramine—Discomfort—Epirubicin—sarcoma	0.000196	0.000983	CcSEcCtD
Imipramine—Malaise—Doxorubicin—sarcoma	0.000194	0.000975	CcSEcCtD
Imipramine—Dry mouth—Epirubicin—sarcoma	0.000194	0.000973	CcSEcCtD
Imipramine—Syncope—Doxorubicin—sarcoma	0.000193	0.00097	CcSEcCtD
Imipramine—Leukopenia—Doxorubicin—sarcoma	0.000193	0.000968	CcSEcCtD
Imipramine—CYP3A4—liver—sarcoma	0.000192	0.00262	CbGeAlD
Imipramine—Confusional state—Epirubicin—sarcoma	0.000192	0.000962	CcSEcCtD
Imipramine—Palpitations—Doxorubicin—sarcoma	0.000191	0.000956	CcSEcCtD
Imipramine—HRH1—lymph node—sarcoma	0.00019	0.00259	CbGeAlD
Imipramine—Oedema—Epirubicin—sarcoma	0.00019	0.000954	CcSEcCtD
Imipramine—Anaphylactic shock—Epirubicin—sarcoma	0.00019	0.000954	CcSEcCtD
Imipramine—Loss of consciousness—Doxorubicin—sarcoma	0.00019	0.000951	CcSEcCtD
Imipramine—Infection—Epirubicin—sarcoma	0.000189	0.000948	CcSEcCtD
Imipramine—CYP2D6—liver—sarcoma	0.000189	0.00257	CbGeAlD
Imipramine—Shock—Epirubicin—sarcoma	0.000187	0.000939	CcSEcCtD
Imipramine—Convulsion—Doxorubicin—sarcoma	0.000187	0.000937	CcSEcCtD
Imipramine—Nervous system disorder—Epirubicin—sarcoma	0.000187	0.000936	CcSEcCtD
Imipramine—Thrombocytopenia—Epirubicin—sarcoma	0.000186	0.000934	CcSEcCtD
Imipramine—Hypertension—Doxorubicin—sarcoma	0.000186	0.000934	CcSEcCtD
Imipramine—Tachycardia—Epirubicin—sarcoma	0.000186	0.000931	CcSEcCtD
Imipramine—Skin disorder—Epirubicin—sarcoma	0.000185	0.000927	CcSEcCtD
Imipramine—ABCB1—lymphoid tissue—sarcoma	0.000185	0.00252	CbGeAlD
Imipramine—Hyperhidrosis—Epirubicin—sarcoma	0.000184	0.000922	CcSEcCtD
Imipramine—Anxiety—Doxorubicin—sarcoma	0.000183	0.000918	CcSEcCtD
Imipramine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—sarcoma	0.000182	0.000914	CcSEcCtD
Imipramine—Discomfort—Doxorubicin—sarcoma	0.000181	0.00091	CcSEcCtD
Imipramine—Anorexia—Epirubicin—sarcoma	0.000181	0.000909	CcSEcCtD
Imipramine—Dry mouth—Doxorubicin—sarcoma	0.00018	0.000901	CcSEcCtD
Imipramine—Confusional state—Doxorubicin—sarcoma	0.000177	0.00089	CcSEcCtD
Imipramine—Anaphylactic shock—Doxorubicin—sarcoma	0.000176	0.000883	CcSEcCtD
Imipramine—Oedema—Doxorubicin—sarcoma	0.000176	0.000883	CcSEcCtD
Imipramine—Infection—Doxorubicin—sarcoma	0.000175	0.000877	CcSEcCtD
Imipramine—Shock—Doxorubicin—sarcoma	0.000173	0.000868	CcSEcCtD
Imipramine—Nervous system disorder—Doxorubicin—sarcoma	0.000173	0.000866	CcSEcCtD
Imipramine—Thrombocytopenia—Doxorubicin—sarcoma	0.000172	0.000864	CcSEcCtD
Imipramine—Insomnia—Epirubicin—sarcoma	0.000172	0.000863	CcSEcCtD
Imipramine—Tachycardia—Doxorubicin—sarcoma	0.000172	0.000861	CcSEcCtD
Imipramine—Skin disorder—Doxorubicin—sarcoma	0.000171	0.000857	CcSEcCtD
Imipramine—Paraesthesia—Epirubicin—sarcoma	0.000171	0.000857	CcSEcCtD
Imipramine—Hyperhidrosis—Doxorubicin—sarcoma	0.00017	0.000853	CcSEcCtD
Imipramine—Somnolence—Epirubicin—sarcoma	0.000169	0.000848	CcSEcCtD
Imipramine—ABCB1—bone marrow—sarcoma	0.000168	0.00229	CbGeAlD
Imipramine—Anorexia—Doxorubicin—sarcoma	0.000168	0.000841	CcSEcCtD
Imipramine—Dyspepsia—Epirubicin—sarcoma	0.000167	0.00084	CcSEcCtD
Imipramine—Decreased appetite—Epirubicin—sarcoma	0.000165	0.000829	CcSEcCtD
Imipramine—Gastrointestinal disorder—Epirubicin—sarcoma	0.000164	0.000824	CcSEcCtD
Imipramine—Fatigue—Epirubicin—sarcoma	0.000164	0.000822	CcSEcCtD
Imipramine—Constipation—Epirubicin—sarcoma	0.000163	0.000816	CcSEcCtD
Imipramine—Insomnia—Doxorubicin—sarcoma	0.000159	0.000798	CcSEcCtD
Imipramine—Paraesthesia—Doxorubicin—sarcoma	0.000158	0.000793	CcSEcCtD
Imipramine—Feeling abnormal—Epirubicin—sarcoma	0.000157	0.000786	CcSEcCtD
Imipramine—Somnolence—Doxorubicin—sarcoma	0.000156	0.000785	CcSEcCtD
Imipramine—Gastrointestinal pain—Epirubicin—sarcoma	0.000156	0.00078	CcSEcCtD
Imipramine—Dyspepsia—Doxorubicin—sarcoma	0.000155	0.000777	CcSEcCtD
Imipramine—Decreased appetite—Doxorubicin—sarcoma	0.000153	0.000767	CcSEcCtD
Imipramine—Gastrointestinal disorder—Doxorubicin—sarcoma	0.000152	0.000762	CcSEcCtD
Imipramine—Fatigue—Doxorubicin—sarcoma	0.000152	0.000761	CcSEcCtD
Imipramine—Urticaria—Epirubicin—sarcoma	0.000151	0.000758	CcSEcCtD
Imipramine—Constipation—Doxorubicin—sarcoma	0.00015	0.000755	CcSEcCtD
Imipramine—Abdominal pain—Epirubicin—sarcoma	0.00015	0.000754	CcSEcCtD
Imipramine—Body temperature increased—Epirubicin—sarcoma	0.00015	0.000754	CcSEcCtD
Imipramine—Feeling abnormal—Doxorubicin—sarcoma	0.000145	0.000727	CcSEcCtD
Imipramine—Gastrointestinal pain—Doxorubicin—sarcoma	0.000144	0.000722	CcSEcCtD
Imipramine—ABCB1—testis—sarcoma	0.000144	0.00196	CbGeAlD
Imipramine—Urticaria—Doxorubicin—sarcoma	0.00014	0.000701	CcSEcCtD
Imipramine—Abdominal pain—Doxorubicin—sarcoma	0.000139	0.000698	CcSEcCtD
Imipramine—Body temperature increased—Doxorubicin—sarcoma	0.000139	0.000698	CcSEcCtD
Imipramine—Asthenia—Epirubicin—sarcoma	0.000136	0.000684	CcSEcCtD
Imipramine—ABCB1—liver—sarcoma	0.000136	0.00185	CbGeAlD
Imipramine—Pruritus—Epirubicin—sarcoma	0.000135	0.000675	CcSEcCtD
Imipramine—Diarrhoea—Epirubicin—sarcoma	0.00013	0.000653	CcSEcCtD
Imipramine—Asthenia—Doxorubicin—sarcoma	0.000126	0.000633	CcSEcCtD
Imipramine—Dizziness—Epirubicin—sarcoma	0.000126	0.000631	CcSEcCtD
Imipramine—Pruritus—Doxorubicin—sarcoma	0.000125	0.000625	CcSEcCtD
Imipramine—Vomiting—Epirubicin—sarcoma	0.000121	0.000607	CcSEcCtD
Imipramine—Diarrhoea—Doxorubicin—sarcoma	0.00012	0.000604	CcSEcCtD
Imipramine—Rash—Epirubicin—sarcoma	0.00012	0.000602	CcSEcCtD
Imipramine—Dermatitis—Epirubicin—sarcoma	0.00012	0.000601	CcSEcCtD
Imipramine—Headache—Epirubicin—sarcoma	0.000119	0.000598	CcSEcCtD
Imipramine—Dizziness—Doxorubicin—sarcoma	0.000116	0.000584	CcSEcCtD
Imipramine—Nausea—Epirubicin—sarcoma	0.000113	0.000567	CcSEcCtD
Imipramine—Vomiting—Doxorubicin—sarcoma	0.000112	0.000561	CcSEcCtD
Imipramine—Rash—Doxorubicin—sarcoma	0.000111	0.000557	CcSEcCtD
Imipramine—Dermatitis—Doxorubicin—sarcoma	0.000111	0.000556	CcSEcCtD
Imipramine—Headache—Doxorubicin—sarcoma	0.00011	0.000553	CcSEcCtD
Imipramine—Nausea—Doxorubicin—sarcoma	0.000105	0.000524	CcSEcCtD
Imipramine—ABCB1—lymph node—sarcoma	0.000104	0.00142	CbGeAlD
Imipramine—CHRM4—Signaling by GPCR—HRAS—sarcoma	5.09e-07	0.000249	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—KDR—sarcoma	5.07e-07	0.000248	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—CCND1—sarcoma	5.06e-07	0.000247	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—CCND1—sarcoma	5.05e-07	0.000247	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—JUN—sarcoma	5.05e-07	0.000247	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—JUN—sarcoma	5.04e-07	0.000246	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—KDR—sarcoma	5.02e-07	0.000246	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—KDR—sarcoma	5.01e-07	0.000245	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—CTNNB1—sarcoma	5.01e-07	0.000245	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—CTNNB1—sarcoma	5e-07	0.000245	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—EGFR—sarcoma	4.97e-07	0.000243	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—CREB1—sarcoma	4.95e-07	0.000242	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—EGFR—sarcoma	4.95e-07	0.000242	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—MDM2—sarcoma	4.93e-07	0.000241	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—IL2—sarcoma	4.89e-07	0.000239	CbGpPWpGaD
Imipramine—CHRM5—Signaling by GPCR—HRAS—sarcoma	4.87e-07	0.000238	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—KIT—sarcoma	4.79e-07	0.000234	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—NRAS—sarcoma	4.79e-07	0.000234	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—CCND1—sarcoma	4.77e-07	0.000233	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—ENO2—sarcoma	4.76e-07	0.000233	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—JUN—sarcoma	4.76e-07	0.000233	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—EGFR—sarcoma	4.73e-07	0.000231	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—HBA1—sarcoma	4.73e-07	0.000231	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—CTNNB1—sarcoma	4.72e-07	0.000231	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—KIT—sarcoma	4.71e-07	0.00023	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—NRAS—sarcoma	4.71e-07	0.00023	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—KIT—sarcoma	4.7e-07	0.00023	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—NRAS—sarcoma	4.7e-07	0.00023	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—KRAS—sarcoma	4.7e-07	0.00023	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—KIT—sarcoma	4.69e-07	0.000229	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—NRAS—sarcoma	4.69e-07	0.000229	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—IL2—sarcoma	4.69e-07	0.000229	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—KIT—sarcoma	4.67e-07	0.000228	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—NRAS—sarcoma	4.67e-07	0.000228	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—KRAS—sarcoma	4.67e-07	0.000228	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—KIT—sarcoma	4.63e-07	0.000226	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—NRAS—sarcoma	4.63e-07	0.000226	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—KIT—sarcoma	4.62e-07	0.000226	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—NRAS—sarcoma	4.62e-07	0.000226	CbGpPWpGaD
Imipramine—ADRA1D—Signaling by GPCR—HRAS—sarcoma	4.58e-07	0.000224	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—CCND1—sarcoma	4.57e-07	0.000223	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—CREB1—sarcoma	4.56e-07	0.000223	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—JUN—sarcoma	4.56e-07	0.000223	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—SRC—sarcoma	4.53e-07	0.000221	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—CTNNB1—sarcoma	4.52e-07	0.000221	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—SRC—sarcoma	4.52e-07	0.000221	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CREB1—sarcoma	4.49e-07	0.000219	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CREB1—sarcoma	4.48e-07	0.000219	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—KRAS—sarcoma	4.47e-07	0.000219	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CREB1—sarcoma	4.46e-07	0.000218	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CREB1—sarcoma	4.45e-07	0.000217	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—VEGFA—sarcoma	4.41e-07	0.000216	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—IL2—sarcoma	4.41e-07	0.000215	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CREB1—sarcoma	4.41e-07	0.000215	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—VEGFA—sarcoma	4.4e-07	0.000215	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CREB1—sarcoma	4.39e-07	0.000215	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—EGFR—sarcoma	4.36e-07	0.000213	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—NRAS—sarcoma	4.35e-07	0.000213	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—NRAS—sarcoma	4.35e-07	0.000213	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—MDM2—sarcoma	4.3e-07	0.00021	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—CCND1—sarcoma	4.29e-07	0.00021	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—EGFR—sarcoma	4.29e-07	0.00021	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—JUN—sarcoma	4.29e-07	0.00021	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—EGFR—sarcoma	4.28e-07	0.00021	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—MDM2—sarcoma	4.27e-07	0.000209	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—EGFR—sarcoma	4.27e-07	0.000209	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—SRC—sarcoma	4.27e-07	0.000209	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—EGFR—sarcoma	4.26e-07	0.000208	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—CTNNB1—sarcoma	4.25e-07	0.000208	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—EGFR—sarcoma	4.22e-07	0.000206	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—EGFR—sarcoma	4.2e-07	0.000206	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—VEGFA—sarcoma	4.16e-07	0.000203	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—KRAS—sarcoma	4.12e-07	0.000202	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—NRAS—sarcoma	4.11e-07	0.000201	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—MDM2—sarcoma	4.09e-07	0.0002	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—SRC—sarcoma	4.09e-07	0.0002	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—KRAS—sarcoma	4.06e-07	0.000198	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—MYC—sarcoma	4.06e-07	0.000198	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—MYC—sarcoma	4.05e-07	0.000198	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—KRAS—sarcoma	4.05e-07	0.000198	CbGpPWpGaD
Imipramine—CYP3A4—Metabolism—PLCG1—sarcoma	4.04e-07	0.000198	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—KRAS—sarcoma	4.03e-07	0.000197	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—KRAS—sarcoma	4.02e-07	0.000197	CbGpPWpGaD
Imipramine—HTR1A—Signaling by GPCR—HRAS—sarcoma	3.99e-07	0.000195	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—KRAS—sarcoma	3.98e-07	0.000195	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—VEGFA—sarcoma	3.98e-07	0.000195	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—KRAS—sarcoma	3.97e-07	0.000194	CbGpPWpGaD
Imipramine—HTR2C—Signaling by GPCR—HRAS—sarcoma	3.97e-07	0.000194	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—EGFR—sarcoma	3.97e-07	0.000194	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—EGFR—sarcoma	3.96e-07	0.000194	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—NRAS—sarcoma	3.93e-07	0.000192	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—SRC—sarcoma	3.84e-07	0.000188	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—IL2—sarcoma	3.84e-07	0.000188	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—MYC—sarcoma	3.83e-07	0.000187	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—IL2—sarcoma	3.82e-07	0.000187	CbGpPWpGaD
Imipramine—ADRA1B—Signaling by GPCR—HRAS—sarcoma	3.8e-07	0.000186	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—MDM2—sarcoma	3.77e-07	0.000184	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—KRAS—sarcoma	3.75e-07	0.000183	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—VEGFA—sarcoma	3.74e-07	0.000183	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—KRAS—sarcoma	3.74e-07	0.000183	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—CCND1—sarcoma	3.74e-07	0.000183	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—EGFR—sarcoma	3.74e-07	0.000183	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—JUN—sarcoma	3.73e-07	0.000183	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—CCND1—sarcoma	3.72e-07	0.000182	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—JUN—sarcoma	3.72e-07	0.000182	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—MDM2—sarcoma	3.71e-07	0.000181	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—CTNNB1—sarcoma	3.71e-07	0.000181	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—MDM2—sarcoma	3.7e-07	0.000181	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—NRAS—sarcoma	3.7e-07	0.000181	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—MDM2—sarcoma	3.69e-07	0.000181	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—CTNNB1—sarcoma	3.69e-07	0.00018	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—MDM2—sarcoma	3.68e-07	0.00018	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—MYC—sarcoma	3.66e-07	0.000179	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—IL2—sarcoma	3.66e-07	0.000179	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—MDM2—sarcoma	3.64e-07	0.000178	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—MDM2—sarcoma	3.63e-07	0.000178	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—EGFR—sarcoma	3.58e-07	0.000175	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—CCND1—sarcoma	3.56e-07	0.000174	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—JUN—sarcoma	3.56e-07	0.000174	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—KRAS—sarcoma	3.54e-07	0.000173	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—CTNNB1—sarcoma	3.53e-07	0.000173	CbGpPWpGaD
Imipramine—DRD2—Signaling by GPCR—HRAS—sarcoma	3.5e-07	0.000171	CbGpPWpGaD
Imipramine—HTR2A—Signaling by GPCR—HRAS—sarcoma	3.45e-07	0.000169	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—MYC—sarcoma	3.44e-07	0.000168	CbGpPWpGaD
Imipramine—HRH1—Signaling by GPCR—HRAS—sarcoma	3.44e-07	0.000168	CbGpPWpGaD
Imipramine—CHRM1—Signaling by GPCR—HRAS—sarcoma	3.43e-07	0.000168	CbGpPWpGaD
Imipramine—CHRM3—Signaling by GPCR—HRAS—sarcoma	3.42e-07	0.000167	CbGpPWpGaD
Imipramine—CHRM2—Signaling by GPCR—HRAS—sarcoma	3.39e-07	0.000166	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—KRAS—sarcoma	3.39e-07	0.000166	CbGpPWpGaD
Imipramine—ADRA1A—Signaling by GPCR—HRAS—sarcoma	3.38e-07	0.000165	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—IL2—sarcoma	3.37e-07	0.000165	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—EGFR—sarcoma	3.37e-07	0.000165	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—SRC—sarcoma	3.35e-07	0.000164	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—SRC—sarcoma	3.33e-07	0.000163	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—TP53—sarcoma	3.33e-07	0.000163	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—TP53—sarcoma	3.33e-07	0.000163	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—IL2—sarcoma	3.32e-07	0.000162	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—IL2—sarcoma	3.31e-07	0.000162	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—IL2—sarcoma	3.3e-07	0.000161	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—IL2—sarcoma	3.29e-07	0.000161	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—CCND1—sarcoma	3.29e-07	0.000161	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—JUN—sarcoma	3.28e-07	0.00016	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—VEGFA—sarcoma	3.26e-07	0.00016	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—IL2—sarcoma	3.26e-07	0.000159	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—CTNNB1—sarcoma	3.25e-07	0.000159	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—IL2—sarcoma	3.25e-07	0.000159	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—VEGFA—sarcoma	3.25e-07	0.000159	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CCND1—sarcoma	3.23e-07	0.000158	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—JUN—sarcoma	3.23e-07	0.000158	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CCND1—sarcoma	3.23e-07	0.000158	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—NRAS—sarcoma	3.22e-07	0.000158	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—JUN—sarcoma	3.22e-07	0.000157	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CCND1—sarcoma	3.22e-07	0.000157	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—JUN—sarcoma	3.21e-07	0.000157	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—NRAS—sarcoma	3.21e-07	0.000157	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CCND1—sarcoma	3.21e-07	0.000157	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—CTNNB1—sarcoma	3.2e-07	0.000157	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—JUN—sarcoma	3.2e-07	0.000156	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—CTNNB1—sarcoma	3.2e-07	0.000156	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—SRC—sarcoma	3.19e-07	0.000156	CbGpPWpGaD
Imipramine—HTR6—Signaling Pathways—HRAS—sarcoma	3.19e-07	0.000156	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—CTNNB1—sarcoma	3.18e-07	0.000156	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—KRAS—sarcoma	3.18e-07	0.000156	CbGpPWpGaD
Imipramine—HTR7—Signaling Pathways—HRAS—sarcoma	3.18e-07	0.000156	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—CTNNB1—sarcoma	3.17e-07	0.000155	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CCND1—sarcoma	3.17e-07	0.000155	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—JUN—sarcoma	3.17e-07	0.000155	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CCND1—sarcoma	3.17e-07	0.000155	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—JUN—sarcoma	3.16e-07	0.000154	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—CTNNB1—sarcoma	3.14e-07	0.000154	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—TP53—sarcoma	3.14e-07	0.000154	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—CTNNB1—sarcoma	3.14e-07	0.000153	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—VEGFA—sarcoma	3.11e-07	0.000152	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—NRAS—sarcoma	3.07e-07	0.00015	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—TP53—sarcoma	3.01e-07	0.000147	CbGpPWpGaD
Imipramine—CHRM4—Signaling Pathways—HRAS—sarcoma	3e-07	0.000147	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—MYC—sarcoma	3e-07	0.000147	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—MYC—sarcoma	2.99e-07	0.000146	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—SRC—sarcoma	2.94e-07	0.000144	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—EGFR—sarcoma	2.94e-07	0.000144	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—EGFR—sarcoma	2.92e-07	0.000143	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—SRC—sarcoma	2.89e-07	0.000142	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—SRC—sarcoma	2.89e-07	0.000141	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—SRC—sarcoma	2.88e-07	0.000141	CbGpPWpGaD
Imipramine—CHRM5—Signaling Pathways—HRAS—sarcoma	2.88e-07	0.000141	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—SRC—sarcoma	2.87e-07	0.00014	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—VEGFA—sarcoma	2.86e-07	0.00014	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—MYC—sarcoma	2.86e-07	0.00014	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—SRC—sarcoma	2.84e-07	0.000139	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—SRC—sarcoma	2.83e-07	0.000139	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—NRAS—sarcoma	2.83e-07	0.000138	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—TP53—sarcoma	2.83e-07	0.000138	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—VEGFA—sarcoma	2.82e-07	0.000138	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—VEGFA—sarcoma	2.81e-07	0.000138	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—VEGFA—sarcoma	2.8e-07	0.000137	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—EGFR—sarcoma	2.8e-07	0.000137	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—VEGFA—sarcoma	2.79e-07	0.000137	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—NRAS—sarcoma	2.78e-07	0.000136	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—NRAS—sarcoma	2.78e-07	0.000136	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—KRAS—sarcoma	2.77e-07	0.000136	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—NRAS—sarcoma	2.77e-07	0.000135	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—VEGFA—sarcoma	2.77e-07	0.000135	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—NRAS—sarcoma	2.76e-07	0.000135	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—VEGFA—sarcoma	2.76e-07	0.000135	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—KRAS—sarcoma	2.76e-07	0.000135	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—NRAS—sarcoma	2.73e-07	0.000134	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—NRAS—sarcoma	2.73e-07	0.000133	CbGpPWpGaD
Imipramine—ADRA1D—Signaling Pathways—HRAS—sarcoma	2.71e-07	0.000132	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—KRAS—sarcoma	2.64e-07	0.000129	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—MYC—sarcoma	2.64e-07	0.000129	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—MYC—sarcoma	2.59e-07	0.000127	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—MYC—sarcoma	2.59e-07	0.000127	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—MYC—sarcoma	2.58e-07	0.000126	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—EGFR—sarcoma	2.58e-07	0.000126	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—MYC—sarcoma	2.57e-07	0.000126	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—MYC—sarcoma	2.55e-07	0.000125	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—MYC—sarcoma	2.54e-07	0.000124	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—EGFR—sarcoma	2.54e-07	0.000124	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—EGFR—sarcoma	2.53e-07	0.000124	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—EGFR—sarcoma	2.52e-07	0.000123	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—EGFR—sarcoma	2.52e-07	0.000123	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—EGFR—sarcoma	2.49e-07	0.000122	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—EGFR—sarcoma	2.48e-07	0.000121	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—TP53—sarcoma	2.47e-07	0.000121	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—TP53—sarcoma	2.45e-07	0.00012	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—KRAS—sarcoma	2.44e-07	0.000119	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—KRAS—sarcoma	2.4e-07	0.000117	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—KRAS—sarcoma	2.39e-07	0.000117	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—KRAS—sarcoma	2.38e-07	0.000117	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—KRAS—sarcoma	2.38e-07	0.000116	CbGpPWpGaD
Imipramine—HTR1A—Signaling Pathways—HRAS—sarcoma	2.36e-07	0.000115	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—KRAS—sarcoma	2.35e-07	0.000115	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—TP53—sarcoma	2.35e-07	0.000115	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—KRAS—sarcoma	2.35e-07	0.000115	CbGpPWpGaD
Imipramine—HTR2C—Signaling Pathways—HRAS—sarcoma	2.35e-07	0.000115	CbGpPWpGaD
Imipramine—ADRA1B—Signaling Pathways—HRAS—sarcoma	2.25e-07	0.00011	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—TP53—sarcoma	2.16e-07	0.000106	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—TP53—sarcoma	2.13e-07	0.000104	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—TP53—sarcoma	2.13e-07	0.000104	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—TP53—sarcoma	2.12e-07	0.000104	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—TP53—sarcoma	2.11e-07	0.000103	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—TP53—sarcoma	2.09e-07	0.000102	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—TP53—sarcoma	2.09e-07	0.000102	CbGpPWpGaD
Imipramine—DRD2—Signaling Pathways—HRAS—sarcoma	2.07e-07	0.000101	CbGpPWpGaD
Imipramine—HTR2A—Signaling Pathways—HRAS—sarcoma	2.04e-07	9.96e-05	CbGpPWpGaD
Imipramine—HRH1—Signaling Pathways—HRAS—sarcoma	2.03e-07	9.94e-05	CbGpPWpGaD
Imipramine—CHRM1—Signaling Pathways—HRAS—sarcoma	2.03e-07	9.91e-05	CbGpPWpGaD
Imipramine—CHRM3—Signaling Pathways—HRAS—sarcoma	2.02e-07	9.87e-05	CbGpPWpGaD
Imipramine—CHRM2—Signaling Pathways—HRAS—sarcoma	2e-07	9.78e-05	CbGpPWpGaD
Imipramine—ADRA1A—Signaling Pathways—HRAS—sarcoma	1.99e-07	9.75e-05	CbGpPWpGaD
